Culture and Imaging of Human Nasal Epithelial Organoids
December 17th, 2021
4K views
A detailed protocol is presented here to describe an in vitro organoid model from human nasal epithelial cells. The protocol has options for measurements requiring standard laboratory equipment, with additional possibilities for specialized equipment and software.
Overview
This article presents a detailed protocol for creating an in vitro organoid model using human nasal epithelial cells. The model is designed to facilitate the study of cystic fibrosis by allowing for the assessment of CFTR activity and its correlation with organoid characteristics.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Organoid Models
Background
- Cystic fibrosis is characterized by dysfunctional ion transport.
- Human nasal epithelial organoids (HNE organoids) can mimic the disease state.
- Understanding CFTR activity is crucial for individualized therapy.
- The model allows for various experimental designs.
Purpose of Study
- To develop a methodology for culturing and imaging HNE organoids.
- To correlate organoid lumen size with CFTR activity.
- To provide a versatile tool for researchers studying cystic fibrosis.
Methods Used
- Culture of human nasal epithelial cells to form organoids.
- Imaging techniques to assess organoid structure.
- Measurement of CFTR activity through organoid characteristics.
- Adaptation of protocols for various laboratory settings.
Main Results
- HNE organoids exhibit lumens that vary in size based on CFTR activity.
- Distinct differences between CF and non-CF organoids were observed.
- The model can be tailored to different experimental needs.
- Insights into ion transport dysfunction were gained.
Conclusions
- The HNE organoid model is a valuable tool for cystic fibrosis research.
- It enables the study of epithelial ion transport and its implications.
- This model can aid in the development of personalized therapies.
Frequently Asked Questions
What are HNE organoids?
HNE organoids are three-dimensional structures derived from human nasal epithelial cells used to study cystic fibrosis.
How do HNE organoids relate to cystic fibrosis?
They mimic the disease state and allow researchers to assess CFTR activity and ion transport dysfunction.
What is the significance of lumen size in organoids?
Lumen size correlates with CFTR activity, helping to distinguish between healthy and diseased states.
Can the protocol be adapted for different labs?
Yes, the protocol includes options for both standard and specialized laboratory equipment.
What applications can the HNE model be used for?
It can be used for various experimental designs related to cystic fibrosis and epithelial ion transport.
Is this model suitable for personalized therapy research?
Yes, it provides insights that can contribute to individualized treatment strategies for cystic fibrosis patients.
Executive Industry Relevance
Human nasal epithelial organoids provide a physiologically relevant in vitro model for assessing CFTR activity, enabling early-stage target validation and mechanistic de-risking in cystic fibrosis drug discovery. By correlating lumen morphology with ion transport function, the model supports predictive confidence in lead identification and portfolio triage. This approach reduces reliance on less predictive systems and accelerates translational continuity from discovery to preclinical evaluation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of CFTR function as a therapeutic target through direct measurement of lumen area as a functional readout.
- Operational Value: Supports biological de-risking by distinguishing CF from non-CF phenotypes based on epithelial fluid transport dynamics.
- Predictive Value: Facilitates hypothesis testing of CFTR modulators by quantifying baseline and compound-induced changes in organoid morphology.
Screening & Assay Development
- Assay Readiness: Generates quantitative, imaging-based outputs (lumen-to-total area ratio) suitable for high-content screening platforms.
- Reproducibility: Standardized organoid culture and fixation protocols ensure consistent morphological readouts across experiments.
- Scalability: Compatible with multi-well angiogenesis slides, enabling parallel testing of multiple conditions or compounds.
Translational & Preclinical Research
- Disease Relevance: Models human nasal epithelial pathophysiology, providing a disease-relevant system for CFTR-directed therapies.
- Translational Continuity: Bridges in vitro findings to preclinical validation by maintaining epithelial polarity and ciliary function.
- Risk-Adjusted Advancement: Supports go/no-go decisions based on functional CFTR restoration observed in organoid swelling assays.
Pipeline & Workflow Integration
The HNE organoid model fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for CFTR modulators.
- Discovery Biology: Enables mechanistic de-risking by linking genetic or pharmacological perturbations to functional ion transport outcomes.
- Screening: Delivers quantitative, imaging-based phenotypic readouts that support assay standardization and compound profiling.
- Analytics: Provides baseline lumen ratio and dose-response data (e.g., forskolin-induced swelling) to compare therapeutic conditions.
- Translational Research: Maintains epithelial differentiation and mucociliary phenotypes, supporting continuity to preclinical models.
- Enterprise Reuse: Establishes a reusable platform for epithelial ion transport studies beyond CF, including primary ciliary dyskinesia and other airway epithelia disorders.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in CFTR modulation by providing direct, visual correlation between compound treatment and epithelial fluid transport.
- Operational Value: Promotes assay standardization through defined imaging and analysis workflows (e.g., polygonal ROI, lumen segmentation).
- Strategic Value: Improves capital efficiency by enabling early prediction of clinical response, reducing late-stage failure risk.
- Portfolio Impact: Supports risk-adjusted prioritization of CFTR modulators based on organoid-derived functional thresholds.
Implementation Considerations
- Requires expertise in primary cell culture, organoid handling, and confocal or fluorescent microscopy.
- Dependent on access to extracellular matrix (e.g., Matrigel), differentiation media, and histology-grade fixation tools.
- Necessitates standardized training for consistent organoid seeding, imaging, and analysis across teams.
- Adaptation to alternative epithelial sources may require optimization of differentiation and expansion conditions.
- Practical limitations include organoid loss during fixation and staining, necessitating sufficient starting cell numbers.
Biopharma FAQs
Why does lumen area measurement matter for CFTR target validation?
Lumen area serves as a quantitative, imaging-based readout of CFTR-mediated fluid transport, enabling direct assessment of channel activity in human nasal epithelial organoids. This measurement distinguishes CF from non-CF phenotypes based on epithelial fluid secretion dynamics. It provides a functional endpoint for evaluating CFTR modulator efficacy in preclinical discovery.
How does isolating the independent variable (e.g., CFTR modulation) fit the discovery pipeline?
By using isogenic or patient-derived organoids with defined CFTR genotypes, researchers can isolate the effect of pharmacological compounds on ion transport. This approach minimizes confounding variables and supports mechanistic de-risking of target engagement. It enables clear attribution of phenotypic changes to CFTR-specific modulation in early discovery.
What quantitative dependent variable measurements enable CFTR functional assessment?
The baseline lumen ratio—calculated as lumen area divided by total organoid surface area—provides a normalized, quantitative metric of CFTR activity. Changes in this ratio following compound exposure (e.g., forskolin) indicate functional restoration or inhibition. These measurements support dose-response modeling and comparative analysis across experimental conditions.
Why do replication requirements matter for cross-functional collaboration in organoid-based assays?
Replication ensures that observed differences in lumen size or swelling response are robust and not due to technical variability in organoid culture or imaging. Consistent readouts across wells, slides, and experiments enable reliable data sharing between biology, screening, and analytics teams. This standardization is essential for building confidence in assay transferability and multi-site validation.
What statistical analysis capabilities are required before implementing HNE organoid assays in a discovery setting?
Implementation requires the ability to quantify lumen and total organoid areas from imaging data, compute lumen ratios, and perform statistical comparisons (e.g., t-tests, ANOVA) across conditions. Data export to Excel or similar platforms enables downstream analysis of dose-response and variability. These capabilities support objective, data-driven go/no-go decisions in lead optimization.
Chapters in this video
0:04
Introduction
1:40
Cell Culture and Expansion of Nasal Epithelial Cells
4:23
Growth and Differentiation of Organoids in Slides and Culture Inserts
6:06
Isolation and Fixation of Organoids
7:36
Preparation and Isolation of Organoids for Histological Sectioning
8:57
Baseline Lumen Measurements
9:56
Results: Live and Fixed Imaging of the Airway Epithelial Organoids Derived from Nasal Epithelial Cells and Analysis Methods
12:21
Conclusion
